The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).
 
Rutika Mehta
Honoraria - Bristol-Myers Squibb; NCCN; NCCN/Pfizer (I); Pfizer/EMD Serono (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb (I); Lilly
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences (I); Natera; Seagen (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; QED Therapeutics; SERVIER; Taiho Oncology
Speakers' Bureau - Incyte; Lilly
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Maria E Martinez Jimenez
No Relationships to Disclose
 
Kirsten Blue
No Relationships to Disclose
 
Trenton Avriett
No Relationships to Disclose
 
Emily Kelbert
No Relationships to Disclose
 
Kara Miller
Consulting or Advisory Role - Pfizer
 
Christopher Ray
No Relationships to Disclose
 
Tiffany Valone
No Relationships to Disclose
 
Woojoo Lee
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Dae Won Kim
Research Funding - Bold Therapeutics